Mylan and Biocon to Present New Data at the American Society of Clinical Oncology (ASCO) Annual Meeting Reinforcing the Efficacy, Safety and Immunogenicity of OgivriTM, the first biosimilar for Herceptin® approved by FDA
(WorldNews Netherlands)

HERTFORDSHIRE, Englandand PITTSBURGHand BENGALURU, India, June 1, 2018/PRNewswire / -- Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1-5. The HERITAGE study compared OgivriTM, the first biosimilar for Herceptin® approved in the U.S., to the reference product in patients with metastatic breast cancer in combination with taxanes for the first 24 weeks and then as a monotherapy until progression. Data obtained after 48 weeks of treatment will be included as part of the Clinical Science Symposium titled,...